Precision Particle Fabrication® technology is the term for Orbis’ patented process to create uniform microspheres and microcapsules in a single-step process.
Yes. Orbis Biosciences exclusively owns or controls relevant patent rights. Our Co-founder and Chief Scientific Officer, Cory Berkland, is an inventor of this technology.
Scalable production rates are obtained using a modular, multi-nozzle approach. For example, a nozzle with ~100 individual jets creating particles 100 micron in diameter can achieve rates in the range of 1-10 kg per minute, depending on a number of factors, including the material and particle architecture. Production rates are particle size dependent, with larger particles and more jets both increasing production rates. Production rates are highest when matrix materials and active ingredients can be melted prior to Precision Particle Fabrication® technology processing while rates decrease as the level of solvent required to dissolve matrix and active ingredients increases.
The cost for producing microspheres and microcapsules using Stratum technology is very similar to the cost for emulsion polymerization processes, whereas the cost for producing microspheres and microcapsules using Optimum technology is very similar to the cost for spray congealing processes, including “spinning disc.” Lastly, the excipients used in Unisun’s film-forming agent are commonly available materials that are no more expensive than ingredients used in tableting pills.
Yes. For example, a dog study demonstrated the capability of an Orbis-fabricated microsphere depot to sustain NSAID blood levels with infusion-like kinetics, without ‘burst’ release. This study was published in the J. Vet. Pharmacol. Therap., 2011. We also have human clinical data on our taste-masked reverse enteric prednisone powder, which demonstrated bioequivalence in total body exposure to the reference listed tablet.